Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
NCT ID: NCT00272558
Last Updated: 2009-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2004-09-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
NCT04287829
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT02784171
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
NCT00256282
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
NCT02863055
Metronomic Therapy in Patients With Metastatic Melanoma
NCT01542255
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Endpoint is response rate, secondary endpoints survival and toxicity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin and Vinorelbine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age above 18 years
* Performance status 0-2
Exclusion Criteria
* Normal renal, liver and bone marrow function
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens B Sorensen, MD
Role: STUDY_CHAIR
Dept. Oncology, Rigshospitalet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. Oncol., Rigshospitalet
Copenhagen, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPM phase II Carbo/VNB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.